Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine, Venetoclax, and ATRA in Newly Diagnosed Acute Myeloid Leukemia
NCT05654194Phase 3Completed
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Oct 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of azacitidine, venetoclax and tretinoin in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Complete Response Rate at 4 weeks. Started Oct 2022; status: completed.
02
Drugs
azacitidinevenetoclaxtretinoin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05654194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05654194.